Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/TRIB1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TRIB1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TRIB1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TRIB1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/TRIB1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/TRIB1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TRIB1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004217630 | Thyroid | HT | regulation of protein catabolic process | 70/1272 | 391/18723 | 5.96e-14 | 1.66e-11 | 70 |
GO:190336230 | Thyroid | HT | regulation of cellular protein catabolic process | 50/1272 | 255/18723 | 7.98e-12 | 1.48e-09 | 50 |
GO:190305030 | Thyroid | HT | regulation of proteolysis involved in cellular protein catabolic process | 40/1272 | 221/18723 | 1.09e-08 | 9.17e-07 | 40 |
GO:005134830 | Thyroid | HT | negative regulation of transferase activity | 45/1272 | 268/18723 | 1.49e-08 | 1.20e-06 | 45 |
GO:004573230 | Thyroid | HT | positive regulation of protein catabolic process | 40/1272 | 231/18723 | 3.91e-08 | 2.65e-06 | 40 |
GO:004586230 | Thyroid | HT | positive regulation of proteolysis | 54/1272 | 372/18723 | 9.68e-08 | 5.67e-06 | 54 |
GO:190336430 | Thyroid | HT | positive regulation of cellular protein catabolic process | 30/1272 | 155/18723 | 1.61e-07 | 8.85e-06 | 30 |
GO:006113630 | Thyroid | HT | regulation of proteasomal protein catabolic process | 33/1272 | 187/18723 | 3.78e-07 | 1.70e-05 | 33 |
GO:200005830 | Thyroid | HT | regulation of ubiquitin-dependent protein catabolic process | 30/1272 | 164/18723 | 5.75e-07 | 2.44e-05 | 30 |
GO:000989629 | Thyroid | HT | positive regulation of catabolic process | 63/1272 | 492/18723 | 8.49e-07 | 3.45e-05 | 63 |
GO:003243430 | Thyroid | HT | regulation of proteasomal ubiquitin-dependent protein catabolic process | 26/1272 | 134/18723 | 1.01e-06 | 3.99e-05 | 26 |
GO:003133129 | Thyroid | HT | positive regulation of cellular catabolic process | 56/1272 | 427/18723 | 1.63e-06 | 6.16e-05 | 56 |
GO:000646924 | Thyroid | HT | negative regulation of protein kinase activity | 33/1272 | 212/18723 | 6.62e-06 | 1.95e-04 | 33 |
GO:003367324 | Thyroid | HT | negative regulation of kinase activity | 35/1272 | 237/18723 | 1.16e-05 | 3.05e-04 | 35 |
GO:000193327 | Thyroid | HT | negative regulation of protein phosphorylation | 45/1272 | 342/18723 | 1.54e-05 | 3.80e-04 | 45 |
GO:004232627 | Thyroid | HT | negative regulation of phosphorylation | 49/1272 | 385/18723 | 1.62e-05 | 3.95e-04 | 49 |
GO:004593629 | Thyroid | HT | negative regulation of phosphate metabolic process | 54/1272 | 441/18723 | 1.86e-05 | 4.39e-04 | 54 |
GO:001056329 | Thyroid | HT | negative regulation of phosphorus metabolic process | 54/1272 | 442/18723 | 1.99e-05 | 4.60e-04 | 54 |
GO:190370627 | Thyroid | HT | regulation of hemopoiesis | 47/1272 | 367/18723 | 2.05e-05 | 4.68e-04 | 47 |
GO:003109820 | Thyroid | HT | stress-activated protein kinase signaling cascade | 35/1272 | 247/18723 | 2.84e-05 | 6.14e-04 | 35 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TRIB1 | SNV | Missense_Mutation | | c.616N>G | p.Leu206Val | p.L206V | Q96RU8 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
TRIB1 | SNV | Missense_Mutation | | c.1015N>A | p.Glu339Lys | p.E339K | Q96RU8 | protein_coding | tolerated(0.45) | benign(0.003) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
TRIB1 | SNV | Missense_Mutation | rs138022510 | c.947G>A | p.Arg316His | p.R316H | Q96RU8 | protein_coding | deleterious(0.03) | probably_damaging(0.986) | TCGA-AO-A03O-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
TRIB1 | SNV | Missense_Mutation | | c.424N>C | p.Asn142His | p.N142H | Q96RU8 | protein_coding | tolerated(0.53) | benign(0.115) | TCGA-B6-A0RS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
TRIB1 | insertion | Frame_Shift_Ins | novel | c.565_566insACCC | p.Ile189AsnfsTer22 | p.I189Nfs*22 | Q96RU8 | protein_coding | | | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TRIB1 | insertion | Nonsense_Mutation | novel | c.566_567insTTGGGTATTTGCAAGTCTAGAGCTTTAGG | p.Val190TrpfsTer9 | p.V190Wfs*9 | Q96RU8 | protein_coding | | | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TRIB1 | insertion | Frame_Shift_Ins | novel | c.742_743insCTTGTAAGCTCCAGCATTATGAATACTATTTGGGGCTTTGCCTC | p.Tyr248SerfsTer17 | p.Y248Sfs*17 | Q96RU8 | protein_coding | | | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
TRIB1 | insertion | Frame_Shift_Ins | novel | c.507dupC | p.Tyr170LeufsTer40 | p.Y170Lfs*40 | Q96RU8 | protein_coding | | | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
TRIB1 | SNV | Missense_Mutation | novel | c.974N>G | p.Glu325Gly | p.E325G | Q96RU8 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-ZJ-AB0I-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TRIB1 | SNV | Missense_Mutation | rs776955393 | c.1039A>G | p.Ile347Val | p.I347V | Q96RU8 | protein_coding | tolerated(0.54) | benign(0) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |